N-((4S,7S,10S)-12-(2-((2-amino-2-oxoethyl)(3-azidopropyl)amino)-2-oxoethyl)-3,4,6,7,9,10,17-heptamethyl-21-(3-(6-(4-methylpiperazin-1-yl)-1H,3'H-[2,5'-bibenzo[d]imidazol]-2'-yl)phenoxy)-2,5,8,11,18-pentaoxo-3,6,9,12,17-pentaazahenicosyl)-N-(2-(N-methyl-4-(3-(6-(4-methylpiperazin-1-yl)-1H,3'H-[2,5'-bibenzo[d]imidazol]-2'-yl)phenoxy)butanamido)ethyl)-6-propiolamidohexanamide

ID: ALA5271458

Chembl Id: CHEMBL5271458

Max Phase: Preclinical

Molecular Formula: C96H123N25O12

Molecular Weight: 1819.20

Associated Items:

Names and Identifiers

Canonical SMILES:  C#CC(=O)NCCCCCC(=O)N(CCN(C)C(=O)CCCOc1cccc(-c2nc3ccc(-c4nc5ccc(N6CCN(C)CC6)cc5[nH]4)cc3[nH]2)c1)CC(=O)N(C)[C@@H](C)C(=O)N(C)[C@@H](C)C(=O)N(C)[C@@H](C)C(=O)N(CCCCN(C)C(=O)CCCOc1cccc(-c2nc3ccc(-c4nc5ccc(N6CCN(C)CC6)cc5[nH]4)cc3[nH]2)c1)CC(=O)N(CCCN=[N+]=[N-])CC(N)=O

Standard InChI:  InChI=1S/C96H123N25O12/c1-12-84(123)99-38-15-13-14-27-87(126)120(52-47-113(8)86(125)29-21-54-133-74-26-19-24-68(56-74)91-102-76-35-31-70(58-80(76)106-91)93-104-78-37-33-72(60-82(78)108-93)118-50-45-111(6)46-51-118)62-88(127)114(9)64(2)94(129)115(10)65(3)95(130)116(11)66(4)96(131)121(63-89(128)119(61-83(97)122)42-22-39-100-109-98)41-17-16-40-112(7)85(124)28-20-53-132-73-25-18-23-67(55-73)90-101-75-34-30-69(57-79(75)105-90)92-103-77-36-32-71(59-81(77)107-92)117-48-43-110(5)44-49-117/h1,18-19,23-26,30-37,55-60,64-66H,13-17,20-22,27-29,38-54,61-63H2,2-11H3,(H2,97,122)(H,99,123)(H,101,105)(H,102,106)(H,103,107)(H,104,108)/t64-,65-,66-/m0/s1

Standard InChI Key:  XFBGGWUWLDYZKP-MHKGRQNNSA-N

Alternative Forms

  1. Parent:

    ALA5271458

    ---

Associated Targets(Human)

MBNL1 Tbio Muscleblind-like protein 1 (34431 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1819.20Molecular Weight (Monoisotopic): 1817.9783AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Zamani F, Suzuki T..  (2021)  Synthetic RNA Modulators in Drug Discovery.,  64  (11.0): [PMID:34060847] [10.1021/acs.jmedchem.1c00154]

Source